Isotechnika Pharma Inc. (ISA.TO) Reports First Quarter 2013 Financial Results
5/16/2013 10:09:17 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO) Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
12/27/2012 8:44:57 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO)'s NICAM Compounds Demonstrate Positive Anti-Hepatitis C Virus Activity in Secondary Level Testing at National Institutes of Health (NIH)-Funded Labs
12/7/2012 9:42:04 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO) Reports Third Quarter 2012 Financial Results
11/14/2012 7:30:13 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO)'s NICAM Portfolio Demonstrates Positive Anti-Viral Activity Against Several Important Viruses
11/6/2012 9:31:04 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO) Announces Close of Second Tranche of Private Placement of Units
10/31/2012 6:45:03 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO) Reports Second Quarter 2012 Financial Results
8/15/2012 9:26:05 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO) Receives Additional Funding From the Government of Canada for NICAM Program
7/17/2012 9:26:22 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO)'s Partner Lux Biosciences Completes Enrollment in Phase 3 Uveitis Study
7/9/2012 9:09:10 AM
More...
|
Isotechnika Pharma Inc. (ISA.TO) to Present at JMP Securities Healthcare Conference
7/5/2012 9:25:46 AM
More...
|
|